Pharma Two B
Dr. David Sidransky, serving on the Board as an external Director since June 2014, in accordance with the Israeli law , is a renowned oncologist and research scientist who was profiled by TIME magazine in 2001 as one of the top physicians and scientists in America. He is widely recognized for his work with early detection of cancer. Dr. Sidransky serves as the Director of the Head and Neck Cancer Research Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and is a Professor of Oncology, Otolaryngology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at John Hopkins University and Hospital. He has authored more than 450 peer-reviewed publications, and has contributed to more than 60 cancer reviews and chapters. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. He has been the recipient of numerous awards and honors, including the 1997 Sarstedt International Prize from the German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating Smoking and Health by the American College of Chest Physicians, and the 2004 Hinda Rosenthal Award presented by the American Association of Cancer Research. Dr. Sidransky previously served as Vice Chairman of the Board of Directors of ImClone. He is Chairman of the Board of Champions Oncology and Tamir Biotechnology, and is on the Board of Directors of Rosetta Genomics Ltd., Immune Pharmaceuticals Inc., Celsus Therapeutics Plc and Advaxis, Inc. He is a current and previous member of scientific advisory boards of corporations and institutions, including Amgen, MedImmune, Roche and Veridex, LLC (a Johnson & Johnson diagnostic company). In Addition, Dr. Sidransky served as Director of The American Association for Cancer Research from 2005 to 2008. Dr. Sidransky has been a member of the Audit, Renumberation and Research & Development committees since June of 2014. He received his B.A. from Brandeis University and his M.D. from the Baylor College of Medicine.